Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05959590 · ClinicalTrials.gov registry record · Phase 1
Ferumoxytol-enhanced Imaging of Osteomyelitis
A Phase 1 study, sponsored by University of New Mexico.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT05959590 is a Phase 1 study that has completed, run by University of New Mexico. The registered enrollment target is 12 participants.
The verdict
NCT05959590, a Phase 1 study, has completed, sponsored by University of New Mexico.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Diabetic foot infections contribute to 75,000 hospitalizations in the US each year. There is a lifetime incidence of 15-25% of foot infections in diabetics. The investigators hypothesize that ferumoxytol (FDA approved for use in CKD patients, unlike gadolinium) will improve the accuracy of MR imaging in the diagnosis of osteomyelitis by allowing for the specific imaging of macrophages that have taken up the iron-based compound. In this study the investigators will image 12 patients with suspected diabetic osteomyelitis using ferumoxytol-contrasted MRI, and evaluate the feasibility of this approach.
Interventions
- DRUG Ferumoxides 11.2Mg Solution for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-02-12 |
| Est. Completion | 2019-08-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05959590
The ClinicalTrials.gov registry entry for NCT05959590 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of New Mexico, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ferumoxides 11.2Mg Solution for Injection is the first listed.
NCT05959590 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05959590 about?
NCT05959590 is a clinical study titled "Ferumoxytol-enhanced Imaging of Osteomyelitis". Diabetic foot infections contribute to 75,000 hospitalizations in the US each year. There is a lifetime incidence of 15-25% of foot infections in diabetics. The investigators hypothesize that ferumoxytol (FDA approved for use in CKD patients, unlike gadolinium) will improve the accuracy of MR imagin...
What is the current status of trial NCT05959590?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2014-02-12. Estimated completion is 2019-08-12.
What interventions are being tested in trial NCT05959590?
The interventions under investigation include: Ferumoxides 11.2Mg Solution for Injection (DRUG).
Who is sponsoring clinical trial NCT05959590?
This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.